May 17, 2024

Pharstoma Inc.
CEO
Masahiko Kubota

Pharstoma Co., Ltd. (Headquarters: Toranomon, Minato-ku, Tokyo; President and CEO: Masahiko Kubota) is pleased to announce that our seed investment round has successfully closed, having received sufficient support from our investors.

As a result, we are now able to commence the development of oral insulin medication. Despite insulin being available for over 100 years, the development of an oral form remains unrealized, and we are dedicated to achieving this milestone.

We specialize in ultra-fine bubble water originating from Japan and are confident that this technology will bring us close to realization. While there are no precedents, we have strong scientific grounds to believe in its feasibility, which we will substantiate through upcoming validations. This marks a significant step forward.

We extend our heartfelt gratitude to all our investors, particularly to Granfoods Co., Ltd. (Headquarters: Yoyogi, Shibuya-ku, Tokyo; President and CEO: Yuichiro Ogawa), and look forward to their continued support.

Within this year, we aim to calculate the BA rate at the animal testing level as a key metric and, based on this evidence, launch our Series A funding round. We believe our business will have even greater value by that time.

We sincerely appreciate your continued support and guidance.

Pharstoma Inc.

For inquiries, please contact us here.